ALKEON CAPITAL MANAGEMENT LLC 13D and 13G filings for ORIC Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-13 09:42 am Purchase |
2024-09-30 | 13G | ORIC Pharmaceuticals, Inc. ORIC |
ALKEON CAPITAL MANAGEMENT LLC | 3,904,096 5.500% |
300,000 (+8.32%) |
Filing |
| 2024-02-13 6:43 pm Purchase |
2023-12-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC |
ALKEON CAPITAL MANAGEMENT LLC | 3,604,096 6.600% |
1,204,844 (+50.22%) |
Filing |
| 2023-02-13 10:15 am Purchase |
2022-12-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC |
ALKEON CAPITAL MANAGEMENT LLC | 2,399,252 6.100% |
2,399,252 (New Position) |
Filing |